leisure time -WSS

leisure time

author：leisure time 2025-09-02 08:18:19 - browse：3625

insulin biosimilar — The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. Jacquelyn Martin/AP

A group representing clinical labs across the country sued the Food and Drug Administration on Wednesday over the agency’s plan to actively regulate lab-developed tests.

The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. When the FDA finalized its test regulation plan last month, several experts said it was only a matter of time until someone in the lab industry sued.

Tests made in labs have historically gone unregulated by the FDA, as the agency considered them low-risk when it started regulating medical devices in 1976. But the tests have since become more numerous and complex, and the regulatory gray area enabled unreliable tests to thrive and harm patients. Infamous examples include Theranos’ blood tests, as well as misleading prenatal genetic tests from a range of companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： What Kate Middleton's cancer revelation might teach the world

entertainment

hotspot

WSS

Erich Jarvis studies song birds to learn about human stuttering

Let's speed up science by embracing open access publishing

Chinese researcher claims birth of first gene

Intellia reports positive results for its CRISPR

Asbestos ban is immediate, but health effects will linger for decades

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

Steward Health Care expansion into Malta flopped

Bright Health sells Medicare Advantage business to Molina

With trial win, GSK could get blood cancer drug back on market

At least 13 dead in Texas as scorching temps continue

Texas board proposes rules on abortion law emergency exemption

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

entertainment

Change Healthcare can notify patients about the breach, HHS says

CRISPR technology availability, affordability needs to be expanded

Ultragenyx gene therapy for rare liver ailment succeeds in late

At ASCO, AstraZeneca reports strong data for breast cancer drug

ASCO: Palliative care found as helpful given virtually as in person

Testing GLP

entertainment

hotspot

leisure time

knowledge